Epidemiology and genotype diversity of norovirus infections among children aged <5 years following rotavirus vaccine introduction in Blantyre, Malawi.


Journal

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
ISSN: 1873-5967
Titre abrégé: J Clin Virol
Pays: Netherlands
ID NLM: 9815671

Informations de publication

Date de publication:
02 2020
Historique:
received: 24 09 2019
revised: 04 12 2019
accepted: 17 12 2019
pubmed: 28 12 2019
medline: 15 5 2021
entrez: 28 12 2019
Statut: ppublish

Résumé

Following rotavirus vaccine introduction, norovirus has emerged as a significant pathogen associated with acute gastroenteritis among children in some high- and middle-income countries. In a case-control study following rotavirus vaccination in Malawi, we used PCR to test for multiple enteric pathogens in fecal samples from children aged <5 years hospitalized with diarrhea, and from asymptomatic community controls (Iturriza-Gómara et al. 2019). To describe the epidemiology and genotype diversity of norovirus infections among infants and young children in Blantyre, Malawi, following rotavirus vaccine introduction in 2012. We analysed data from the case-control study to assess annual and agespecific norovirus prevalence and the presence of co-infection. Norovirus-containing specimens were amplified by PCR and sequenced to determined genotype. Norovirus prevalence in cases was similar for each complete year of study (11.4% in 2013, 9.3% in 2014 and 11.2% in 2015). Prevalence of norovirus among children aged <6 months, 6-11 months, 12-23 months and 24+ months was 15.3% (11/72), 13.3% (44/331), 11.0% (24/219) and 6.6% (4/61) respectively in cases and 6.7% (2/30), 13.1% (30/229), 4.2% (8/192) and 7.1 (5/70) in controls. Co-pathogens were commonly detected in norovirus positive cases (77/83) and controls (44/45). Norovirus GII.4 was the most commonly identified genotype, comprising 48% and 41% of genotyped strains among cases and controls, respectively. Norovirus disease prevalence was unchanged during the study period, and was greatest amongst infants. Frequent co-infection and asymptomatic shedding suggests intense community transmission of norovirus and other enteric pathogens in this low-income, African setting.

Sections du résumé

BACKGROUND
Following rotavirus vaccine introduction, norovirus has emerged as a significant pathogen associated with acute gastroenteritis among children in some high- and middle-income countries. In a case-control study following rotavirus vaccination in Malawi, we used PCR to test for multiple enteric pathogens in fecal samples from children aged <5 years hospitalized with diarrhea, and from asymptomatic community controls (Iturriza-Gómara et al. 2019).
OBJECTIVES
To describe the epidemiology and genotype diversity of norovirus infections among infants and young children in Blantyre, Malawi, following rotavirus vaccine introduction in 2012.
STUDY DESIGN
We analysed data from the case-control study to assess annual and agespecific norovirus prevalence and the presence of co-infection. Norovirus-containing specimens were amplified by PCR and sequenced to determined genotype.
RESULTS
Norovirus prevalence in cases was similar for each complete year of study (11.4% in 2013, 9.3% in 2014 and 11.2% in 2015). Prevalence of norovirus among children aged <6 months, 6-11 months, 12-23 months and 24+ months was 15.3% (11/72), 13.3% (44/331), 11.0% (24/219) and 6.6% (4/61) respectively in cases and 6.7% (2/30), 13.1% (30/229), 4.2% (8/192) and 7.1 (5/70) in controls. Co-pathogens were commonly detected in norovirus positive cases (77/83) and controls (44/45). Norovirus GII.4 was the most commonly identified genotype, comprising 48% and 41% of genotyped strains among cases and controls, respectively.
CONCLUSIONS
Norovirus disease prevalence was unchanged during the study period, and was greatest amongst infants. Frequent co-infection and asymptomatic shedding suggests intense community transmission of norovirus and other enteric pathogens in this low-income, African setting.

Identifiants

pubmed: 31881509
pii: S1386-6532(19)30278-1
doi: 10.1016/j.jcv.2019.104248
pii:
doi:

Substances chimiques

Rotavirus Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

104248

Subventions

Organisme : Wellcome Trust
ID : 201945/Z/16/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 091909/Z/10/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 102464/Z/13/A
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 102466/Z/13/A
Pays : United Kingdom

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

Daniel Hungerford (D)

Centre for Global Vaccine Research, Institute of Infection and Global Health, University of Liverpool, Members of Liverpool Health Partners, Ronald Ross Building, 8 West Derby Street, Liverpool, L69 7BE, UK; NIHR, Health Protection Research Unit in Gastrointestinal Infections at University of Liverpool, L69 3GL, Liverpool, United Kingdom. Electronic address: d.hungerford@liverpool.ac.uk.

Khuzwayo C Jere (KC)

Centre for Global Vaccine Research, Institute of Infection and Global Health, University of Liverpool, Members of Liverpool Health Partners, Ronald Ross Building, 8 West Derby Street, Liverpool, L69 7BE, UK; Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi; Department of Medical Laboratory Sciences, College of Medicine, University of Malawi, Blantyre, Malawi.

Naor Bar-Zeev (N)

Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi; International Vaccine Access Center, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.

John P Harris (JP)

NIHR, Health Protection Research Unit in Gastrointestinal Infections at University of Liverpool, L69 3GL, Liverpool, United Kingdom.

Nigel A Cunliffe (NA)

Centre for Global Vaccine Research, Institute of Infection and Global Health, University of Liverpool, Members of Liverpool Health Partners, Ronald Ross Building, 8 West Derby Street, Liverpool, L69 7BE, UK.

Miren Iturriza-Gómara (M)

Centre for Global Vaccine Research, Institute of Infection and Global Health, University of Liverpool, Members of Liverpool Health Partners, Ronald Ross Building, 8 West Derby Street, Liverpool, L69 7BE, UK; NIHR, Health Protection Research Unit in Gastrointestinal Infections at University of Liverpool, L69 3GL, Liverpool, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH